New and future drug development for gastroesophageal reflux disease

Carla Maradey-Romero, Ronnie Fass, Carla Maradey-Romero, Ronnie Fass

Abstract

Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.

Keywords: Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors.

Conflict of interest statement

Conflicts of interest: Ronnie Fass is a reasearcher for Mederi Therapeutics; speaker for Takeda, Astrazeneca and Eisai; and a consultant for Takeda and Given Imaging.

References

    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920.
    1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717.
    1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. Published Online First: 13 Jul 2013. gutjnl-2012-304269.
    1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–1187.
    1. Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ., 3rd Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456.
    1. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810.
    1. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)-an update. J Neurogastroenterol Motil. 2010;16:8–21.
    1. Hershcovici T, Fass R. Gastro-oesophageal reflux disease beyond proton pump inhibitor therapy. Drugs. 2011;71:2381–2389.
    1. Fass R. Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment. Clin Gastroenterol Hepatol. 2012;10:338–345.
    1. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.
    1. Fass R. Proton Pump Inhibitor Failure - what are the therapeutic options? Am J Gastroenterol. 2009;104(suppl 2):S33–S38.
    1. Fass R, Shapiro M, Dekel R, Sewell J. Systematic Review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79–94.
    1. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol. 2010;26:389–394.
    1. Fass R, Hixson LJ, Ciccolo ML, Gordon P, Hunter G, Rappaport W. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician. 1997;55:205–212. 217–218.
    1. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2 suppl 1):S9–S31.
    1. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11:4067–4077.
    1. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as inicitial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965–973.
    1. Fujiwara Y, Higuchi K, Nebiki H, et al. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2005;21(suppl 2):10–18.
    1. Pappa KA, Gooch WM, Buaron K, et al. Low-dose ranitidine for the relief of heartburn. Aliment Pharmacol Ther. 1999;13:459–465.
    1. Pappa KA, Williams BO, Payne JE, Buaron KS, Mussari KL, Ciociola AA. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther. 1999;13:467–473.
    1. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335–1339.
    1. Iwakiri K, Kawami N, Sano H, et al. The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects. J Smooth Muscle Res. 2011;47:157–166.
    1. Ohara S, Haruma K, Kinoshita Y, Kusano M. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol. 2010;45:1219–1227.
    1. Inamori M, Iida H, Hosono K, et al. The histamine H2 receptor antagonist lafutidine in Japanese patients with non-erosive reflux disease. Hepatogastroenterology. 2010;57:1430–1434.
    1. Dewan B, Philipose N. Lafutidine 10 mg versus rabeprazole 20 mg in the treatment of patients with heartburn-dominant uninvestigated dyspepsia: a randomized, multicentric trial. Gastroenterol Res Pract. 2011;2011:640685.
    1. Gatehouse D, Wedd DJ, Paes D, et al. Investigations into the genotoxic potential of loxtidine, a long-acting H2 receptor antagonist. Mutagenesis. 1988;3:57–68.
    1. NCT00405119. A study to investigate the effectiveness of AH234844 (Lavoltidine) compared with nexium and ranitidine. [accessed November 2013]. Available from URL: .
    1. NCT00551473. Open-label comparison of 24hr gastric pH on Days 1, 2, 7 with once-daily administration of Lavoltidine 40 mg. [accessed November 2013]. Available from URL: .
    1. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625–632.
    1. Scarpignato C. New drugs to suppress acid secretion: current and future developments. Drug Discov Today Ther Strateg. 2007;4:155–163.
    1. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther. 2000;22:266–280.
    1. Howden CW. Appropriate acid suppression in the treatment of acid-related conditions. Pharmacol Ther. 1994;63:123–134.
    1. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;(2):CD003244.
    1. Dean BB, Gano AD, Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.
    1. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235–1240.
    1. Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med. 2011;43:366–374.
    1. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29:824–833.
    1. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731–741.
    1. Fass R, Chey WD, Zakko SF, et al. Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and night-time heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261–1272.
    1. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421–431.
    1. Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10:247–253.
    1. Galmiche JP, Bruley Des Varannes S, Ducrotté P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy subjects. Aliment Pharmacol Ther. 2004;19:655–662.
    1. Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23:1179–1187.
    1. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther. 2010;31:648–657.
    1. Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep. 2010;12:437–447.
    1. Hunt RH, Armstrong D, Yaghoobi M, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther. 2008;28:187–199.
    1. Wang L, Zhou L, Hu H, Lin S, Xia J. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin. 2012;28:101–109.
    1. Wang L, Zhou L, Lin S, Hu H, Xia J. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastroenterol. 2011;45:322–329.
    1. DU YQ, Guo WY, Zou DW, et al. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis. 2012;13:113–119.
    1. NCT00471094. Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis (NCT00471094) [accessed November 2013]. Available from URL: .
    1. Hanmi Pharmaceutical Co., Ltd. Hamni press center, latest news. [accessed November 2013]. Available from URL: .
    1. U.S Food and Drug Administration (FDA) FDA/Center for Drug Evaluation and Research Office of Communications, Division of Online Communications. [accessed November 2013]. Available from URL: .
    1. Chowers Y, Atarot T, Kostadinov A, et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology. 2008;134(suppl):A172.
    1. Chowers Y, Atarot T, Pratha VS, Fass R. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil. 2012;24:426–431. e208–e209.
    1. Orexo announces results confirming the clinical profile of OX17 in reflux disease (GERD) [accessed November 2013]. Available from URL: .
    1. Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am. 2013;42:93–117.
    1. Sorba G, Galli U, Cena C, et al. A new furoxan NO-donor rabeprazole derivative and related compounds. Chembiochem. 2003;4:899–903.
    1. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294–307.
    1. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:1385–1391.
    1. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20–26.
    1. Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007;321:866–874.
    1. Choi HY, Noh YH, Jin SJ, et al. Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers. Clin Ther. 2012;34:1999–2010.
    1. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797–804.
    1. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB) J Med Chem. 2012;55:4446–4456.
    1. Hershcovici T, Mashimo H, Fass R. The lower esophageal sphincter. Neurogastroenterol Motil. 2011;23:819–830.
    1. Rohof WO, Aronica E, Beaumont H, Troost D, Boeckxystaens GE. Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study. Neurogastroenterol Motil. 2012;24:383, e173.
    1. Lehmann A, Blackshaw LA, Brändén L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology. 2002;123:1129–1134.
    1. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol. 2009;156:153–162.
    1. Scarpellini E, Blondeau K, Boecxstaens V, et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther. 2011;33:730–737.
    1. Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs. 2003;63:1785–1797.
    1. Clavé P, González A, Moreno A, et al. Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology. 1998;115:597–604.
    1. Zerbib F, Bruley Des Varannes S, Scarpignato C, et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol. 1998;275(6 Pt 1):G1266–G1273.
    1. Beglinger C, Degen L, Schroller S, D'Amato M, Persiani S. Oral itriglumide, a specific CCK2/gastrin receptor antagonist, inhibits gastrin stimulated gastric acid secretion in humans. Gut. 2004;54(suppl VII):A36.
    1. Hershcovici T, Fass R. Transient lower esophageal sphincter relaxation reducers - have we hit a brick wall? Aliment Pharmacol Ther. 2011;33:1256–1257.
    1. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther. 2009;330:911–921.
    1. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen Placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2011;106:1427–1438.
    1. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology. 2010;139:409–417.
    1. Boeckxstaens GE, Beaumont H, Hatlebakk J, Silberg D, Adler J, Denison H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology. 2009;136(suppl 1):A436.
    1. Zerbib F, Bruley des Varannes S, Roman S, et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2011;33:911–921.
    1. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012;35:1231–1242.
    1. Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12:35–40.
    1. Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45:413–421.
    1. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol. 2005;11:4210–4214.
    1. Rohof WO, Bennink RJ, de Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut. 2012;61:1670–1677.
    1. Mertens V, Blondeau K, Pauwels A, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci. 2009;54:972–979.
    1. Frampton JE. Prucalopride. Drugs. 2009;69:2463–2476.
    1. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study. Aliment Pharmacol Ther. 2008;27:404–411.
    1. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther. 2011;33:1113–1122.
    1. Fass R. Functional heartburn: what it is and how to treat it. Gastrointest Endosc Clin N Am. 2009;19:23–33.
    1. Hershcovici T, Achem SR, Jha LK, Fass R. Systematic review: the treatment of noncardiac chest pain. Aliment Pharmacol Ther. 2012;35:5–14.
    1. Fass R, Dickman R. Non-cardiac chest pain: an update. Neurogastroenterol Motil. 2006;18:408–417.
    1. Kort ME, Kym PR. TRPV1 antagonists: clinical setbacks and prospects for future development. Prog Med Chem. 2012;51:57–70.
    1. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today. 2009;14:56–67.
    1. Adachi K, Furuta K, Miwa H, et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-eroxive reflux disease. Dig Dis Sci. 2012;57:1609–1617.
    1. Araki H, Kato T, Onogi F, et al. Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificial ulcer healing after endoscopic submucosal dissection with dissection size > 40 mm. J Clin Biochem Nutr. 2012;51:185–188.
    1. Kawahara Y, Nakase Y, Isomoto Y, et al. Role of macrophage colony-stimulating factor (M-CSF)-dependent macrophages in gastric ulcer healing in mice. J Physiol Pharmacol. 2011;62:441–448.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다